Image by Pexels from Pixabay
Scientists have developed a technique that could significantly reduce the time to discover potential new antibody-based drugs to treat disease.
Antibodies are produced by the body in response to the presence of a disease-causing agent. They can also be synthesised in the laboratory to mimic natural antibodies and are used to treat a number of diseases.
Antibody therapies can be highly effective, but challenges can arise when promising candidate antibodies are produced at a large scale. Stresses encountered during manufacturing can disrupt the structure of these fragile proteins leading to aggregation and loss of activity. This in turn prevents them from being made into a therapeutic.
New research from an eight-year collaboration between scientists at Leeds and the biopharmaceutical company AstraZeneca has resulted in a technique that allows fragments of antibodies to be screened for susceptibility to aggregation caused by structure disruption much earlier in the drug discovery process.
The approach is described by the researchers in a paper in the journal Nature Communications, published today.
Dr David Brockwell, Associate Professor in the Astbury Centre for Structural Molecular Biology at the University, led the research. He said: “Antibody therapeutics have revolutionised medicine. They can be designed to bind to almost any target and are highly specific.
“But a significant problem has been the failure rate of candidates upon manufacturing at industrial scale. This often only emerges at a very late stage in the development process – these drugs are failing at the last hurdle.
“But our research is turning that problem on its head.”
When it comes to developing an antibody drug, scientists are not restricted to a single protein sequence. Fortunately, there is often an array of similar antibodies with the same ability of locking or binding tightly onto a disease-causing agent. That gives researchers a range of proteins to screen, to determine which are more likely to progress through the development process.
“The collaboration demonstrates the power of industry and academia working together to tackle what has been one of the major roadblocks preventing the efficient and rapid development of these powerful therapeutic molecules.”
Professor Sheena Radford, FRS, Director of the Astbury Centre, said: “The collaboration that has existed between the team of scientists within the University of Leeds and AstraZeneca demonstrates the power of industry and academia working together to tackle what has been one of the major roadblocks preventing the efficient and rapid development of these powerful therapeutic molecules.”
How target proteins are screened
The target proteins are cloned into the centre of an enzyme that breaks down antibiotics in the bacterium E.coli. This enables the scientists to directly link antibiotic resistance of the bacteria to how aggregation-prone the antibody fragment is.
A simple readout – bacterial growth on an agar plate containing antibiotic – gives an indication of whether the target protein will survive the manufacturing process. If the antibody proteins are susceptible to stress, they will unfold or clump together, become inactive, and the antibiotic will kill the bacteria. But if the protein chain is more stable, the bacteria thrives and will display antimicrobial resistance and will grow in the presence of the antibiotic.
The scientists harvest the bacteria that have survived and identify the cloned protein sequence. That indicates which protein sequences to take forward in the development pipeline. The whole cycle takes about a month and increases the chances of success.
But the process can go a step further, using the idea of directed evolution.
Scientists use the idea of natural selection where mutations or changes take place in the proteins, sometimes making them more stable. Directed evolution could generate new better performing sequences that, at the current time, cannot even be imagined, let alone designed and manufactured.
How does this method work? Like Darwin’s natural selection, evolutionary pressure in this case is applied by the antibiotic and selects for the survival of bacteria that produce the protein variants that do not aggregate.
The protein sequences hosted in the bacterial cells that have shown resistance are harvested and their genes sequenced and scored, to select the best performing sequences. After a quick check to ensure that the new antibody sequences still retain their excellent binding capability for the original disease-causing target, they can be taken forward for further development.
Professor Radford said: “There is tremendous excitement about this approach. We are letting evolutionary selection change the sequence of the proteins for us and that might make some of them more useful as drug therapies. Importantly for industry, nature does the hard-work – obviating the need for so called rational engineering which is time- and resource-intensive.
“As we do this, we will be putting the sequence information we gather into a database. As the database gets bigger, it may well be possible with artificial intelligence and machine learning to be able to identify the patterns in protein sequences that tell us that a protein can be scaled up for pharmaceutical production without needing any experiments. That is our next challenge and one we are tackling right now.”
“The screening system we have developed here is a great example of industry and academia working together to solve important challenges in the development of potential new medicines.”
Dr David Lowe, who led the work at AstraZeneca, said: “The screening system that we have developed here is a great example of industry and academia working together to solve important challenges in the development of potential new medicines.
“By combining AstraZeneca’s antibody discovery and screening expertise, together with the Astbury Centre’s world-leading knowledge of protein structure and aggregation, we have produced a high throughput method for rapidly evolving proteins with better biophysical properties that has the potential for wide scientific applicability.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Global Bispecific Antibodies Therapy Blincyto Hemlibra Antibody Therapeutics Market Size To Witness 118% Growth To Reach US$ 10 Billion By 2026on October 7, 2020 at 2:38 am
Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights: Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion) Commercially ...
- Experimental treatment used on president is months away from use on regular basison October 6, 2020 at 6:52 am
President Donald Trump is set to leave the hospital on Monday after testing positive for COVID-19 is bringing up a lot of questions about his actual conditions and the treatments ...
- Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastomaon October 5, 2020 at 8:26 pm
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical ...
- President Trump is prescribed a third drug to combat his COVID-19 infectionon October 4, 2020 at 10:34 am
President Donald Trump, who recently tested positive for the coronavirus, is now being treated with dexamethasone, a type of steroid that is often used ...
- Trump has been treated with Remdesivir, his second coronavirus therapy, which is authorized to treat severely ill COVID-19 patientson October 3, 2020 at 5:20 am
The President is currently being treated at Walter Reed hospital . President Donald Trump, who recently tested positive for the coronavirus, has been given a dose o ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Drug Discovery Services Market Share, Size Report 2020 to 2025 Future Trends and Industry Growth Research Report by Industry Research Coon October 6, 2020 at 7:01 am
Final Report will add the analysis of the impact of COVID-19 on this industry." “Drug Discovery Services Market” ...
- Global Small Molecule Drug Discovery Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.comon October 6, 2020 at 5:45 am
COVID-19 Impact and Global Analysis by Therapeutic Area; Process/Phase; and Geography" report has been added to ResearchAndMarkets.com's offering.
- DiamiR Announces Oral Presentation at 21st International Conference on Alzheimer's Drug Discoveryon October 5, 2020 at 11:26 am
DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive ...
- INmune Bio to present preliminary phase I data on Alzheimer’s drug discoveryon October 5, 2020 at 8:46 am
(INMB +4.2%) announces that CJ Barnum PhD, Head of Neurosciences will present data from a Phase Ib study of a biomarker directed XPro1595 in patients with Alzheimer’s disease.
- Nvidia announces partnership with GSK focused on drug discoveryon October 5, 2020 at 7:06 am
Nvidia Corp. shares (NVDA) are up 3% in Monday trading after the company said it would partner with GlaxoSmithKline PLC (GSK.LN) to use computing and artificial intelligence for drug discovery. "GSK ...